PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
复制标题
DOI：
10.1371/journal.pone.0251656
复制
发表时间：
2021
期刊：
影响因子：
3.7
通讯作者：
Anastasi E
中科院分区：
文献类型：
--
作者：
Tartaglione S;Mancini P;Viggiani V;Chirletti P;Angeloni A;Anastasi E
胰腺癌（PDAC）是一种无法治愈的癌症，没有足够的肿瘤标志物。我们之前的研究表明，与目前使用的PDAC生物标志物相比，维生素K缺乏诱导蛋白II（PIVKA-II）的诊断性能更好。用更大的样本量证实我们之前的数据，并评估PIVKA-II在预测手术成功率方面的可能作用。此外，为了进一步评估PDAC细胞直接产生PIVKA-II的假设，我们使用免疫荧光检查了PDAC病例中PIVKA-II的组织表达。我们招募了76名新诊断的PDAC患者，并选择了11名患者在手术切除后测定PIVKA-II水平。在其中一个中进行了PIVKA-II组织表达的免疫荧光（IF）研究。在LUMIPULSE G1200（Fujirebio-Europe，Belgium）上通过荧光酶免疫测定法（CLEIA）测定PIVKA-II血清值。71例患者（94%）的PIVKA-II血清水平高于基线临界值，中位值为464 mAU/Ml（范围27-40783 mAU/mL）;灵敏度和特异性分别为78.67%和90.67%。术前PIVKA-II阳性的患者显示术后中位PIVKA-II血清浓度显著降低（P < 0.015）：诊断时为820（91-40783）mAU/mL，术后为123（31-4666）mAU/mL。PDAC切片上的IF测定证明癌细胞中PIVKA-II表达。这些数据首次显示PDAC患者手术后PIVKA-II血清水平降低，并报告了PDAC组织中的PIVKA-II表达。需要进一步的研究来证实这些发现，并确定PIVKA-II在诊断和监测PDAC患者中的有用性。
Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our previous data with a larger sample size and to assess a possible role of PIVKA-II in predicting surgical success. Additionally, to further evaluate the hypothesis of a direct PIVKA-II production by PDAC cells, we examined PIVKA-II tissue expression in a case of PDAC using immunofluorescence. We enrolled 76 newly diagnosed PDAC patients and selected 11 patients to determine PIVKA-II levels also after surgical resection. An immunofluorescence (IF) study of PIVKA-II tissue expression was carried out in one of them. PIVKA-II serum values were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Belgium). PIVKA-II serum levels were above the cut-off at baseline in 71 patients (94%) with a median value of 464 mAU/Ml (range 27–40783 mAU/mL); the sensitivity and specificity were 78.67% and 90.67% respectively. Patients with pre-operative PIVKA-II positivity showed a significant decrease (P < 0.015) of median PIVKA-II serum concentrations after surgery: 820 (91–40783) mAU/mL at diagnosis vs 123 (31–4666) mAU/mL post-operatively. IF assay on PDAC sections demonstrated PIVKA-II expression in cancer cells. These data are the first showing a decreased PIVKA-II serum levels after surgery in PDAC patients and reporting PIVKA-II expression in PDAC tissue. Further studies are needed to confirm these findings and to determine PIVKA-II usefulness in diagnosing and monitoring PDAC patients.
登录
查看更多内容
影响因子：
1.6
作者：
Saitta C;Raffa G;Alibrandi A;Brancatelli S;Lombardo D;Tripodi G;Raimondo G;Pollicino T
通讯作者：
Pollicino T
影响因子：
10
作者：
Montanari, Elita;Oates, Angela;Matricardi, Pietro
通讯作者：
Matricardi, Pietro
DOI：
10.4291/wjgp.v1.i4.129
发表时间：
2010-10-15
期刊：
World journal of gastrointestinal pathophysiology
影响因子：
--
作者：
Takahashi, Yoshihisa;Inoue, Tohru;Fukusato, Toshio
通讯作者：
Fukusato, Toshio
DOI：
10.3109/00365513.2015.1058521
发表时间：
2015-01-01
影响因子：
2.1
作者：
Dauti, Fredrik;Jonsson, Magnus Hjaltalin;Schott, Ulf
通讯作者：
Schott, Ulf
影响因子：
--
作者：
Dell'Aquila, Emanuela;Fulgenzi, Claudia Angela Maria;Santini, Daniele
通讯作者：
Santini, Daniele